Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Howard D Thames

Showing results (1-10 of 79) with videos related to

Pageof 8
Sort By:
In Vivo (Athens, Greece)|March 31, 2005
New anticancer agents: in vitro and in vivo evaluationDaniel Zips, Howard D Thames, Michael Baumann
International Journal of Radiation Oncology, Biology, Physics|August 12, 2003
In regard to Solomon et al.: EGFR blockade with ZD1839 ("Iressa") potentiates the antitumor effects of single and multiple fractions of ionizing radiation in human A431 squamous cell carcinoma. IJROBP 2003;55:713-723Mechthild Krause, Michael Baumann, Howard D Thames
International Journal of Radiation Oncology, Biology, Physics|January 10, 2017
Rod Withers' Data are Available OnlineHoward D Thames, Nancy R Hunter, Kathy A Mason
International Journal of Radiation Oncology, Biology, Physics|March 31, 2004
Dose-volume conundrum for response of prostate cancer to brachytherapy: summary dosimetric measures and their relationship to tumor control probabilityWarren D D'Souza, Howard D Thames, Deborah A Kuban
Oncology (Williston Park, N.Y.)|June 24, 2004
PSA after radiation for prostate cancerDeborah A Kuban, Howard D Thames, Larry B Levy
International Journal of Radiation Biology|November 4, 2016
The Withers Archive: online availability of H. Rodney Withers' dataHoward D Thames, Nancy R Hunter, Kathryn A Mason
The Journal of Urology|May 10, 2005
Defining recurrence after radiation for prostate cancerDeborah A Kuban, Howard D Thames, William U Shipley
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 30, 2003
Will identifying or targeting altered marker expression in response to cytotoxic therapy be of prognostic or therapeutic value?Christopher H Crane, Howard D Thames, Stanley R Hamilton
World Journal of Urology|August 19, 2003
Radiation for prostate cancer: use of biochemical failure as an endpoint following radiotherapyDeborah A Kuban, Howard D Thames, Larry B Levy
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|December 29, 2016
The Withers archive: Online availability of rod Wither's dataHoward D Thames, N R Hunter, Kathy A Mason
Pageof 8

Showing results (1-10 of 79) with videos related to

Sort By:
Pageof 8
In Vivo (Athens, Greece)|March 31, 2005
New anticancer agents: in vitro and in vivo evaluationDaniel Zips, Howard D Thames, Michael Baumann
International Journal of Radiation Oncology, Biology, Physics|August 12, 2003
In regard to Solomon et al.: EGFR blockade with ZD1839 ("Iressa") potentiates the antitumor effects of single and multiple fractions of ionizing radiation in human A431 squamous cell carcinoma. IJROBP 2003;55:713-723Mechthild Krause, Michael Baumann, Howard D Thames
International Journal of Radiation Oncology, Biology, Physics|January 10, 2017
Rod Withers' Data are Available OnlineHoward D Thames, Nancy R Hunter, Kathy A Mason
International Journal of Radiation Oncology, Biology, Physics|March 31, 2004
Dose-volume conundrum for response of prostate cancer to brachytherapy: summary dosimetric measures and their relationship to tumor control probabilityWarren D D'Souza, Howard D Thames, Deborah A Kuban
Oncology (Williston Park, N.Y.)|June 24, 2004
PSA after radiation for prostate cancerDeborah A Kuban, Howard D Thames, Larry B Levy
International Journal of Radiation Biology|November 4, 2016
The Withers Archive: online availability of H. Rodney Withers' dataHoward D Thames, Nancy R Hunter, Kathryn A Mason
The Journal of Urology|May 10, 2005
Defining recurrence after radiation for prostate cancerDeborah A Kuban, Howard D Thames, William U Shipley
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 30, 2003
Will identifying or targeting altered marker expression in response to cytotoxic therapy be of prognostic or therapeutic value?Christopher H Crane, Howard D Thames, Stanley R Hamilton
World Journal of Urology|August 19, 2003
Radiation for prostate cancer: use of biochemical failure as an endpoint following radiotherapyDeborah A Kuban, Howard D Thames, Larry B Levy
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|December 29, 2016
The Withers archive: Online availability of rod Wither's dataHoward D Thames, N R Hunter, Kathy A Mason
Pageof 8